Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference
Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference
Live moderated webcast with Jeffrey Eisenberg, Chief Executive Officer of Xenetic Biosciences on Tuesday, October 24th at 1:00 PM ET
10月24日，星期二，與遺傳生物科學公司首席執行官傑弗裡·艾森伯格現場直播這是東部時間下午1：00
FRAMINGHAM, MA / ACCESSWIRE / October 11, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat oncology indications, today announced that Jeffrey Eisenberg, Chief Executive Officer of Xenetic Biosciences, will participate at the Virtual Investor Ask the CEO Conference on October 24, 2023 at 1:00 PM ET.
馬薩諸塞州弗雷明翰/ACCESSWIRE/2023年10月11日/亞洲網加利福尼亞州聖克拉拉10月24日電專注於推進創新的免疫腫瘤學技術，解決難以治療的腫瘤學適應症的生物製藥公司Xenetic Biosciences，Inc.(納斯達克代碼：XBIO)(以下簡稱“Xenetic”或“公司”)今天宣佈，Xenetic Biosciences首席執行官傑弗裡·艾森伯格將參加2023年10月24日美國東部時間下午1：00舉行的虛擬投資者問答首席執行官大會。
The "Ask the CEO" conference is intended to provide the investment community with access to ask their questions directly to management. Investors and interested parties will have the opportunity to submit questions live during the event. Questions can also be pre-submitted leading up to the event through virtualinvestorco.com/asktheceo-xbio. Participating companies will answer as many questions as possible during the event.
“向CEO提問”會議旨在為投資界提供直接向管理層提問的渠道。投資者和感興趣的各方將有機會在活動期間現場提交問題。問題也可以在活動前通過ViralInvest orco.com/asktheceo-xbio預先提交。參展公司將在活動期間回答盡可能多的問題。
A live video webcast of the event will be available on the Events page in the Investors section of the Company's website (xeneticbio.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.
該活動的現場視頻網路直播將在公司網站(xeneticBio.com)投資者部分的活動頁面上進行。網路直播重播將在現場演示後兩個小時內播放，並將在90天內播放。
About Xenetic Biosciences
關於遺傳生物科學
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
Xenetic Biosciences，Inc.是一家生物製藥公司，專注於推進創新的免疫腫瘤學技術，以解決難以治療的癌症。該公司的DNase平臺旨在通過瞄準與癌症進展有關的中性粒細胞外陷阱(Net)來改善包括免疫療法在內的現有治療的結果。Xenetic目前專注於將其全身性DNA ase計劃推向臨床，作為胰腺癌和局部晚期或轉移性實體腫瘤的輔助治療。
The Company is also developing its personalized CAR T platform technology, XCART, to develop cell-based therapeutics targeting the unique B-Cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-Cell lymphomas.
該公司還在開發其個性化CAR T平臺技術XCART，以開發針對單個患者惡性腫瘤細胞表面獨特的B細胞受體的基於細胞的療法，用於治療B細胞淋巴瘤。
For more information, please visit the Company's website at and connect on Twitter, LinkedIn, and Facebook.
欲瞭解更多資訊，請訪問公司網站，並連接Twitter、LinkedIn和Facebook。
Contact:
聯繫方式：
JTC Team, LLC
Jenene Thomas
(833) 475-8247}
xbio@jtcir.com
JTC團隊，有限責任公司
珍妮·託馬斯
(833)475-8247}
郵箱：xbio@jtCir.com
SOURCE: Xenetic Biosciences, Inc.
資料來源：Xenetic生物科學公司。
譯文內容由第三人軟體翻譯。